Recent Advances in the Treatment of Alopecia Areata : Episode 3

Opinion

Video

April 3, 2023

Analyzing Phase 3 Clinical Trial Data of Baricitinib in Alopecia Areata

Author(s):

Raj Chovatiya, MD, PhD,George Han, MD, PhD

The expert panel discusses the secondary analysis from the phase 3 BRAVE clinical trials of baricitinib in alopecia areata.

EP: 1.Impact of Alopecia Areata on Quality of Life, and Current Standard of Treatment

EP: 2.JAK Inhibitor Baricitinib for Treatment of Alopecia Areata

EP: 3.Analyzing Phase 3 Clinical Trial Data of Baricitinib in Alopecia Areata

EP: 4.Novel Mechanisms of Action for Treatment of Alopecia Areata

EP: 5.Physician and Patient Communication for the Management of Alopecia Areata

EP: 6.The Pathophysiology of Alopecia Areata

EP: 7.The Benefits of Early Diagnosis of Alopecia Areata

EP: 8.Patient Factors and Other Considerations for Treatment Selection

EP: 9.Treatment Options for Alopecia Areata

EP: 10.Review of FDA Approved JAK Inhibitors for Alopecia Areata

EP: 11.JAK Inhibition in the Treatment of Alopecia Areata

EP: 12.Assessing Risk and Safety of JAK Inhibitors

EP: 13.Real-World Clinical Experience With JAK Inhibitors

EP: 14.Challenges With the Use of JAK Inhibitors

EP: 15.Considerations Regarding Patient Selection for JAK Inhibitors

EP: 16.The Role of Health Care Providers in Raising Awareness About Alopecia Areata

EP: 17.Future Directions in the Treatment of Alopecia Areata

Related Videos

Skin of Color Savvy: The Art and Science of Treating Patients of Color

Crisis Point: Benzene Concerns in Acne Care

Related Content

Related Content

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.